Showing 6201-6210 of 9993 results for "".
- Positive Results for Dermavant's Vtama in Pediatric Maximal Usage Study in Atopic Dermatitishttps://practicaldermatology.com/news/positive-results-for-dermavants-vtama-in-pediatric-maximal-usage-study-in-atopic-dermatitis/2461418/Dermavant Sciences shared positive results from its maximal usage study of Vtama (tapinarof) cream 1% in children down to age 2 years old with extensive burden of atopic dermatitis. “We are delighted with the results from our maximal usage study of Vtama cream 1% in atopic dermati
- Monkeypox Update: Kids Aged 8 or Younger at High Risk for More Severe Monkeypoxhttps://practicaldermatology.com/news/monkey-pox-update-kids-aged-8-or-younger-at-high-risk-for-more-severe-monkeypox/2461409/Children aged 8 years or younger are at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal. Young children would be a key target group for smallpox vaccination and other urgent measures if the outbreak widens, according to the review b
- Extreme Weather and Skin Disease: What’s the Connection?https://practicaldermatology.com/news/extreme-weather-and-skin-disease-whats-the-connection/2461395/As floods, wildfires, and extreme heat events increase in frequency and severity, they pose a significant threat to global dermatological health, as many skin diseases are climate sensitive, according to The Journal of Climate Change and Health. “We wanted to provide dermatol
- Phase 3 Data: Opdivo Reduced Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/phase-3-data-opdivo-reduced-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma/2461391/Bristol Myers Squibb shared results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB
- ASDSA's 2022 Top Advocates Recognizedhttps://practicaldermatology.com/news/asdsas-2022-top-advocates-recognized/2461381/Meet the American Society for Dermatologic Surgery Association (ASDSA) honorees from the fourth annual Top Advocate program Honorees are chosen based on their contribution to various advocacy efforts throughout the year and demonstrated commitment to patient safety in the field of derma
- Crown's Skinpen Scores New Indications in the EU and UKhttps://practicaldermatology.com/news/crowns-skinpen-scores-new-indications-in-the-eu-and-uk/2461375/Crown Aesthetics’ SkinPen Precision scored three new approved indications in the EU and UK. The new&
- Galderma Debuts Sensitive Skincare Facultyhttps://practicaldermatology.com/news/galderma-debuts-sensitive-skincare-faculty/2461372/Reinforcing its commitment to advancing dermatology for every skin story, Galderma has formed a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives. The Faculty will focus on three key pillars of research, innovation, and engagem
- Candesant Biomedical Introduces New SweatTech Initiative at ASDShttps://practicaldermatology.com/news/candesant-biomedical-novel-investigational-technology-for-hyperhydrosis/2461371/Candesant Biomedical is introducing a new initiative – SweatTech™ – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) pat
- Business News: Incyte Buys Startup Villarishttps://practicaldermatology.com/news/business-news-incyte-buys-startup-villaris/2461370/Incyte will pay $70 million upfront to buy Villaris Therapeutics, a startup working on an experimental drug for vitiligo. Villaris’ lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Villaris&
- DermTech Presents on Value of Decentralization of Clinical Trialshttps://practicaldermatology.com/news/dermtech-presents-on-value-of-decentralization-of-clinical-trials/2461368/Technology can help decentralize clinical trials, leading to greater patient satisfaction, a more diverse patient population, better retention and cost savings, according to a presentation by DermTech at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Di